Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RCUS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Domvanalimab | Non-small Cell Lung Cancer | Phase 3 · NCT05502237 | Active not recruiting |
| Nab-paclitaxel | Non-small Cell Lung Cancer | Phase 3 · NCT05502237 | Active not recruiting |
| Casdatifan (AB521) | Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 · NCT07011719 | Recruiting |
| Quemliclustat (AB680) | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 · NCT06608927 | Active not recruiting |
| Zimberelimab | Non-small Cell Lung Cancer | Phase 3 · NCT05502237 | Active not recruiting |
| Sacituzumab Govitecan | Lung Cancer | Phase 2 · NCT05633667 | Active not recruiting |
| Platinum Doublet | Advanced Non-Small Cell Lung Cancer | Phase 2 · NCT05676931 | Active not recruiting |
| Perenostobart (SRF617) | Metastatic Castration-resistant Prostate Cancer | Phase 2 · NCT05177770 | Terminated |
| Irinotecan | Borderline Resectable Pancreatic Adenocarcinoma | Phase 1/2 · NCT05688215 | Recruiting |
| m-FOLFOX-6 regimen | Metastatic Colorectal Cancer | Phase 1/2 · NCT04660812 | Completed |
| modified FOLFIRINOX (Treatment Group C) | Pancreatic Ductal Adenocarcinoma | Phase 2 · NCT06048484 | Recruiting |
| Etrumadenant | Lung Cancer | Phase 2 · NCT05633667 | Active not recruiting |
| Sotigalimab (APX005M) | Pancreatic Cancer | Phase 1/2 · NCT05419479 | Suspended |
| FOLFOX regimen | Rectal Cancer | Phase 2 · NCT05024097 | Recruiting |
| FOLFIRI | Pancreatic Cancer | Phase 1/2 · NCT05419479 | Suspended |
| Volrustomig | Advanced Clear Cell Renal Cell Carcinoma | Phase 1 · NCT07000149 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not RCUS's own candidates): Cisplatin, Gemcitabine Hydrochloride, Fluorouracil, Leucovorin, Durvalumab, Carboplatin, Capecitabine, Nivolumab, Oxaliplatin, Paclitaxel, Pembrolizumab, Cabozantinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RCUS holds $694M in cash and short-term investments (as of Sep 30, 2026) and burns about $103.5M/quarter from operations, an estimated runway of 20.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 22 · Moderate
Based on our existing business plan, we believe that our cash, cash equivalents, and marketable securities as of September 30, 2026, together with the proceeds from our equity financing in October 2026, will be sufficient to fund our planned level of operations into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RCUS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 5%+ holder (13D) | 31,424,760 | 21.82% | 2026-08-05 |
| BlackRock, Inc. | Institution (13G, 5%+) | 12,736,927 | 8.85% | 2025-12-31 |
| Terry J Rosen Chief Executive Officer, Director · +315,000 options |
Insider | 2,236,409 | 1.55% | 2026-01-23 |
| Juan C. Jaen President · +126,000 options |
Insider | 1,200,531 | 0.83% | 2026-07-09 |
| Yasunori Kaneko Director · +16,900 options |
Insider | 957,955 | 0.67% | 2026-06-11 |
| Jennifer Jarrett Chief Operating Officer · +206,583 options |
Insider | 224,024 | 0.16% | 2026-01-23 |
| Carolyn C. Tang General Counsel · +96,000 options |
Insider | 184,607 | 0.13% | 2026-06-11 |
| Kathryn E Falberg Director · +16,900 options |
Insider | 176,406 | 0.12% | 2026-06-11 |
| Richard Markus Chief Medical Officer · +96,000 options |
Insider | 89,647 | 0.06% | 2026-01-23 |
| II Robert C. Goeltz Chief Financial Officer · +96,000 options |
Insider | 84,161 | 0.06% | 2026-05-11 |
| David L. Lacey Director · +16,900 options |
Insider | 76,652 | 0.05% | 2026-06-11 |
| Antoni Ribas Director · +16,900 options |
Insider | 52,853 | 0.04% | 2026-06-11 |
Share count 143,990,614 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RCUS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →